PureTech Health has spied an opportunity to improve on Jazz Pharmaceuticals’ Epidiolex. Armed with its Glyph chemistry platform, the biotech has created an oral capsule formulation of cannabidiol (CBD ...

PureTech Health (PRTC) announces that the board of directors has appointed Robert Lyne as CEO, and as a member of the board of directors, ...

I’m honored to lead PureTech as CEO at such an important moment in its evolution. Over the past two years, I’ve seen ...

Robert Lyne has been named CEO of PureTech Health as the Boston biotech company seeks funding to spin out Celea Therapeutics ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks An announcement from PureTech Health ...

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with ...

BOSTON, July 08, 2025--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of ...

PureTech Health has pieced together a wholly owned pipeline in recent years, picking up a prospect from Teva while taking ownership of Ariya Therapeutics and Alivio Therapeutics. With the expansion ...

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing ...

PureTech Systems Inc., a provider of geospatial AI-boosted video analytics for wide-area perimeter and border security, is proud to announce the integration of its patented PureActiv software with ...

BOSTON, August 18, 2025--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") plans to announce its half-yearly results for the six months ended June 30, 2025, ...

Novartis has offloaded two midphase mTORC1 inhibitors to PureTech Health. The agreement will see PureTech create a subsidiary, resTORbio, to move the assets into a phase 2b trial in diseases linked to ...